Yescarta Becomes Japan’s Second Approved CAR-T
Other Nods For Alunbrig, Calquence, Emgality
Executive Summary
Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing.
You may also be interested in...
Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Healios, Athersys Confident Despite Missed Japan Stroke Endpoint
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.